Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RDIF and ChemRar Launch Final Stage of Favipiravir Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"RUSSIA","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Russian Direct Investment Fund"},{"company":"Russian Direct Investment Fund","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Approval Of Mixing and Matching of COVID Booster Shots By FDA is yet Another Confirmation of Efficacy of Vaccine Cocktail Approach Pioneered by The Russian Sputnik V Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Russian Direct Investment Fund"}]

Russian Direct Investment Fund

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Approval Of Mixing and Matching of COVID Booster Shots By FDA is yet Another Confirmation of Efficacy of Vaccine Cocktail Approach Pioneered by The Russian Sputnik V Vaccin...

Details:

Sputnik V's efficacy against infection with the Delta variant is 83% and 94% against hospitalization. To date Sputnik V has been registered in 70 countries in various parts of the world with total population of over 4 billion people.

Lead Product(s): ChAdOx1 nCoV-19,rAd26-S

Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: AstraZeneca

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 21, 2021

ASK
US

Upload
your Pipeline Activity

Russian Direct Investment Fund

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

RDIF and ChemRar Launch Final Stage of Favipiravir Clinical Trial

Details:

RDIF and ChemRar have applied to the Russian Ministry of Health for the accelerated registration of Favipiravir in accordance with the Russian Government's Decree.

Lead Product(s): Favipiravir

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 22, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY